Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
Reads0
Chats0
TLDR
PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.About:
This article is published in Radiotherapy and Oncology.The article was published on 2013-11-01 and is currently open access. It has received 394 citations till now. The article focuses on the topics: PSA Failure & Androgen deprivation therapy.read more
Citations
More filters
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
Anders Widmark,Adalsteinn Gunnlaugsson,Lars Beckman,Camilla Thellenberg-Karlsson,Morten Høyer,Magnus Lagerlund,Jon Kindblom,Claes Ginman,Bengt Johansson,Kirsten Björnlinger,Mihajl Seke,Måns Agrup,Per Fransson,Björn Tavelin,David Norman,Björn Zackrisson,Harald Anderson,Elisabeth Kjellén,Lars Franzén,Per Nilsson +19 more
TL;DR: There was weak evidence of an increased frequency of acute physician-reported RTOG grade 2 or worse urinary toxicity in the ultra-hypofractionation group at end of radiotherapy, consistent with the physician-evaluated toxicity.
Journal ArticleDOI
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Douglas Brand,Douglas Brand,Alison Tree,Alison Tree,Peter Ostler,Hans van der Voet,Andrew Loblaw,William Chu,Daniel Ford,Shaun Tolan,Suneil Jain,Alexander G.R. Martin,John Staffurth,Philip Camilleri,Kiran Kancherla,John Frew,Andrew K Chan,Ian S. Dayes,Daniel Henderson,Stephanie Brown,Clare Cruickshank,Stephanie Burnett,A. Duffton,Clare Griffin,Victoria Hinder,Kirsty Morrison,Kirsty Morrison,O. Naismith,Emma Hall,Nicholas van As,Nicholas van As,D Dodds,E Lartigau,S Patton,Alan J. Thompson,Mathias Winkler,P Wells,T Lymberiou,Daniel Saunders,M Vilarino-Varela,P Vavassis,Theodoros Tsakiridis,R Carlson,George Rodrigues,Jacob Tanguay,S Iqbal,Scott C. Morgan,A Mihai,A Li,O Din,Miguel Panades,R Wade,Yvonne Rimmer,J Armstrong,N Oommen +54 more
TL;DR: The results suggest that substantially shortening treatment courses with stereotactic body radiotherapy does not increase either gastrointestinal or genitourinary acute toxicity.
Journal ArticleDOI
Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial
Daniel A. Hamstra,Neil Mariados,John Sylvester,Dhiren Shah,Lawrence Karsh,Richard Hudes,David C. Beyer,Steven Kurtzman,Jeffrey A. Bogart,R. Alex Hsi,Michael Kos,Rodney J. Ellis,Mark Logsdon,S.H. Zimberg,Kevin Forsythe,Hong Zhang,Edward Soffen,Patrick Francke,Constantine Mantz,Peter J. Rossi,Theodore L. DeWeese,Stephanie Daignault-Newton,Benjamin W. Fischer-Valuck,Anupama Chundury,Walter Bosch,Jeff M. Michalski +25 more
TL;DR: The benefit of a hydrogel spacer in reducing the rectal dose, toxicity, and QOL declines after image guided intensity modulated radiation therapy for prostate cancer was maintained or increased with a longer follow-up period, providing stronger evidence for the benefit of hydrogels spacer use in prostate radiation therapy.
Journal ArticleDOI
Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study.
Alan J. Katz,Josephine Kang +1 more
TL;DR: SBRT appears to be a safe and effective treatment for high-risk prostate carcinoma and the data suggests that SBRT alone may be the optimal approach.
References
More filters
Journal ArticleDOI
Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients
Alexandru Dasu,Iuliana Toma-Dasu +1 more
TL;DR: The results indicate that the high fractionation sensitivity is an intrinsic property of prostate carcinomas and they support the use of hypofractionation to increase the therapeutic gain for these tumours.
Journal ArticleDOI
Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.
Christopher R. King,Sean P. Collins,Donald B. Fuller,Pin-Chieh Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +6 more
TL;DR: Long-term outcome demonstrates that prostate SBRT is well tolerated and has little lasting impact on health-related quality of life (QOL) outcomes among prostate cancer patients following stereotactic body radiation therapy.
Journal ArticleDOI
Stereotactic body radiotherapy for organ-confined prostate cancer
TL;DR: Preliminary results following stereotactic body radiotherapy (SBRT) treatment for organ-confined prostate cancer are highly encouraging and additional follow-up is needed to determine long-term biochemical control and maintenance of low toxicity and QOL.
Journal ArticleDOI
Acute and Late Toxicity in a Randomized Trial of Conventional Versus Hypofractionated Three-Dimensional Conformal Radiotherapy for Prostate Cancer
Giorgio Arcangeli,Jack F. Fowler,Sara Gomellini,Stefano Arcangeli,Biancamaria Saracino,Maria Grazia Petrongari,Marcello Benassi,Lidia Strigari +7 more
TL;DR: The findings suggest that the hypofractionation regimen used in this study is safe, with only a slight, nonsignificant increase in tolerable and temporary acute toxicity compared with the conventional fractionation schedule.
Journal ArticleDOI
Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.
Jacqueline E Livsey,Richard A Cowan,James P Wylie,Ric Swindell,Graham Read,Vincent Khoo,John P Logue +6 more
TL;DR: These data indicate that the delivery of a relatively low total dose using a hypofractionated regime results in similar tumor control and normal-tissue toxicity to 65-70 Gy delivered in 1.8-2 Gy fractions, and suggest that this is an acceptable regime for good-prognosis patients.
Related Papers (5)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
Fractionation and protraction for radiotherapy of prostate carcinoma
David J. Brenner,Eric J. Hall +1 more